IMAGINE ...a better future for patients WE DO.
Our Vision is that the millions of people across the globe suffering from substance use disorders and serious mental illness have access to evidence-based treatment to change lives.
Our Company was founded to help tackle the opioid crisis, one of the largest and most urgent public health emergencies of our time. Our purpose is to bring science-based, life-transforming treatments to patients. We strive to help eliminate the stigma of addiction. We discovered buprenorphine and developed it as a leading evidence-based treatment for opioid dependence, while concurrently advocating for a more effective recovery care model. Buprenorphine is among the medications for opioid use disorder that is included in the World Health Organization (WHO) essential medication list.1
Medication-assisted treatment (MAT) for opioid use disorder is a critical part of the solution to the global opioid crisis.
MAT is the use of medications, in combination with counseling and behavioral therapies, to provide a “whole-patient” approach to the treatment of substance use disorders.2 While therapy and rehab are powerful tools in opioid use disorder and substance use disorder recovery, science shows that patients who use medication in addition to these treatments experience a higher recovery rate.3
Addiction and mental health are uniquely challenging treatment spaces.
A common misunderstanding about medications used to treat opioid use disorder is that some of the medicines used simply substitute one drug for another.4 However, these medications may restore healthy brain function, which leads to improvements in behaviors associated with addiction. Longer-term use of these medications is associated with improved outcomes.5
We take our role as a responsible steward of these medications extremely seriously.
We cultivate a culture of integrity and commit ourselves to the highest standards of governance. We believe our long-term success is directly linked to operating in a responsible way and in a way that minimizes our impact on the environment. We support efforts to educate around safety and proper use of our medication-assisted treatments.
We are driving forward our understanding of addiction and other serious mental health illnesses to create new science that will help pave the way for an even deeper understanding of patient needs and treatment innovation.
We engage at all levels across the addiction treatment spectrum, interacting with governments, key opinion leaders, physicians, payers, patients, and patient advocacy groups to raise awareness and educate about addiction as a chronic, relapsing disease.
- https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.01
- https://www.samhsa.gov/medication-assisted-treatment
- Substance Abuse and Mental Health Services Administration. (2016). Decisions in Recovery: Medications for Opioid Use Disorder. Decisions in Recovery Treatment for opioid use disorders (HHS Pub No. SMA-16-4993), 2016. Retrieved from: www.samhsa.gov/brss-tacs/recovery-support-tools/shared-decision-making
- SAMSHA2018_TIP63MedicationsForOpioidUseDisorder/p1-3/col2/ para2/bullets1-3 (p.5) Retrieved from: TIP 63: Medications for Opioid Use Disorder – Full Document | SAMHSA Publications and Digital Products
- Leshner, A. I., & Mancher, M. (2019). Summary. In Medications for opioid use disorder save lives (p. 5). essay, The National Academies Press.
